AP13000 LCMS/MS System

本提案的目的是为北卡罗来纳大学教堂山分校（UNC-CH）艾滋病研究中心（CFAR）的临床药理学/分析化学核心（CPACC）和药学院的一组研究人员提供创新和专用的LC/MS/MS技术。据估计，与CFAR相关的研究将利用大约60%的仪器时间。CPACC提供了一个集中的单位，以促进UNC-CH和CFAR合作机构的艾滋病毒/艾滋病相关临床和基础科学研究的药理学和分析研究。在1998年CPACC成立之前，研究人员依靠没有资金的同事不可靠的时间表或将研究外包给昂贵的私人机构，努力满足他们的分析和药理学需求。CPACC的成功最好的例证是，在今年CFAR的五年续期提案中，它从同行评审中获得了出色的分数（CFAR实际上是有把握的）。资助至2006年)。尽管评论者指出“该核心受到专用LC/MS设施的严重限制”，但仍给予了这一杰出评级。UNC-CH缺乏足够的设备，因此有必要通过与葛兰素史克公司的安排，在夜间和周末进行需要LC/MS/MS技术的研究。不幸的是，由于这些资源有限，CFAR不得不拒绝了一些重要的项目。除了CFAR，来自药学院的一小群研究人员将利用40%的仪器时间。这将有助于确保从获得仪器的那一刻起就完全使用该仪器。Richard R. Tidwell博士（CPACC主任）将担任该提案的PI，并负责仪器维护和使用的所有方面。Drs。Hall和Kashuba将优先考虑CPA CC的使用，Gary Pollack博士将优先考虑药学院科学家的使用。仪器将被安置在药学院新装修的空间里。

The purpose of this proposal is to provide innovative and dedicated LC/MS/MS technology to the Clinical Pharmacology/ Analytical Chemistry Core (CPACC) of the University of North Carolina at Chapel Hill (UNC-CH) Center for AIDS Research (CFAR) and a group of researchers in the School of Pharmacy. It is estimated that CFAR related studies will utilize approximately 60% of the instrument time. The CPACC provides a centralized unit to facilitate the pharmacology and analytical studies of HIV/AIDS related clinical and basic science research at UNC-CH and collaborating CFAR institutions. Prior to the establishment of the CPACC in 1998, investigators struggled through their analytical and pharmacology needs by relying on the undependable timetables of unfunded colleagues or by contracting out the studies to costly private facilities. The success of the CPACC can be best exemplified by the outstanding score it received from peer reviewers during the CFARs five-year renewal proposal this year (The CFAR is virtually assured of . funding through 2006). This outstanding rating was given despite the fact the reviewers noted " this core is severely limited by a dedicated LC/MS facility". The lack of sufficient facilities at UNC-CH made it necessary for studies requiring LC/MS/MS technology to be carried out night and weekend via an arrangement with GlaxoSmithKline. Unfortunately, because these resources were limited a number of important projects had to be turned down by the CFAR. In addition to the CFAR, a small group of investigators from the School of Pharmacy will utilize 40% of the instrument time. This will serve to assure complete usage of the instrument from the moment of acquisition. Dr. Richard R. Tidwell (Director of the CPACC) will serve as PI of the proposal and will be responsible for all aspects of instrument maintenance and usage. Drs. Hall and Kashuba will prioritize CPA CC use and Dr. Gary Pollack will prioritize use by School of Pharmacy scientists. The instrument will be housed in newly renovated space in the School of Pharmacy.